VRTX — Expiration of Patent US11578062 related to SYMDEKO
Mar 25, 2031, 12:00:00 AM UTC
Summary
The patent US11578062, associated with Vertex Pharmaceuticals Inc's product SYMDEKO, is set to expire on March 25, 2031. SYMDEKO is a combination drug used to treat cystic fibrosis, comprising a specific active pharmaceutical ingredient, which allows for better patient outcomes. The expiration may open pathways for generic competition, potentially impacting Vertex's market position and revenue from this drug, as generics typically lead to lower prices.
Company
VERTEX PHARMACEUTICALS INC (VRTX)NASDAQ — Healthcare: Manufacturing, Biotechnology: Pharmaceutical Preparations
www.vrtx.comSimilar Events
Expiration of Patent US7495103 for SYMDEKO
The patent US7495103 for the SYMDEKO product, which is associated with Vertex Pharmaceuticals Inc and relates to modulators of ATP-Binding Cassette transporters crucial for treating diseases such as cystic fibrosis, is set to expire on May 20, 2027. The expiration could open the market for generics, potentially impacting Vertex's market position and revenues significantly.
Patent ExpirationExpiration of Patent US8354427 for SYMDEKO
The patent US8354427 for the SYMDEKO product, which modulates ATP-Binding Cassette transporters for the treatment of Cystic Fibrosis, will expire on July 6, 2026. The expiration may impact Vertex Pharmaceuticals Inc's market position, as generics could enter the market following the patent's lapse, potentially affecting revenue from SYMDEKO.
Patent ExpirationPatent Expiry for US11564916 related to SYMDEKO
Patent US11564916 related to SYMDEKO (COPACKAGED), assigned to Vertex Pharmaceuticals Inc, will expire on August 13, 2029. SYMDEKO is a medication that combines two active ingredients indicated for the treatment of cystic fibrosis. The expiration of this patent could allow for the introduction of generic versions, potentially impacting Vertex Pharmaceuticals’ revenue and market position in the cystic fibrosis treatment landscape.
Patent ExpirationPatent Expiration for US10239867 related to SYMDEKO
Vertex Pharmaceuticals Inc. faces patent expiration for US10239867 related to its CFTR modulator product SYMDEKO on April 9, 2027. This patent protects compositions useful in treating diseases mediated by ABC transporters, which play a crucial role in cystic fibrosis management. The expiration of this patent may lead to increased competition in the market for SYMDEKO, potentially impacting Vertex's revenue streams from this product.
Patent Expiration